Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article examines the evidence regarding finasteride's sexual side effects and offers recommendations for patient counseling but reports no new clinical findings.

This study of FAERS data suggests that finasteride, particularly at the 1 mg dosage, is associated with a wide range of adverse effects not previously established in long-term studies, especially among younger men.

This study found no clear evidence that finasteride negatively affects erectile function, though it does cause a reduction in ejaculatory volume and has potential implications for prostate cancer risk.

This review examines the roles of testosterone, dihydrotestosterone, and estradiol in activating male sexual behavior in laboratory animals and humans, reporting no new clinical results.

This review provides an overview of the risks and side effects associated with common medications used to treat benign prostatic hyperplasia, highlighting the importance for clinicians and patients to discuss these aspects for informed decision-making.

This review discusses the sexual side effects of finasteride and dutasteride, two 5-α-reductase inhibitors, and reports no new clinical findings while calling for further research into dosage differences.

This study found that 5-alpha-reductase inhibitor monotherapy for symptomatic benign prostatic hyperplasia showed some clinical benefit over placebo but was linked to a higher incidence of sexual side effects.

This study concluded that mesotherapy with a dutasteride-containing solution was the most effective option for treating androgenetic alopecia in males, promoting hair growth and reducing hair loss.

This meta-analysis found that treating male androgenetic alopecia with 5α-reductase inhibitors increases the risk of sexual dysfunction, with a statistically significant risk for finasteride but not for dutasteride.

This review discusses the effects of 5ARI drugs on male reproductive parameters, reporting potential decreases in sperm count and motility more significantly in men with pre-existing oligozoospermia, but does not provide fertility outcomes.

Bald men are not more virile and may have fewer sexual partners.

Finasteride helps improve hair growth in men with hair loss but may increase the risk of erectile dysfunction.

This review highlights that various commonly prescribed medications for chronic conditions may impact male fertility by affecting hormone secretion, sperm production, ejaculation, erectile function, and libido, although conclusive evidence is limited to specific drug groups.

This review examines the sexual side effects of 5α-reductase inhibitors like finasteride, highlighting the increased risk of erectile dysfunction, libido reduction, and potential contribution to depression without new clinical findings.

In this systematic review, dutasteride may be more effective than finasteride for hair growth in men with androgenetic alopecia, but the comparative magnitude of this effect is highly uncertain.

This source reports that combining 5-alpha reductase inhibitors with minoxidil for treating male androgenic alopecia presents a minimal risk of side effects when administered following established medical guidelines, with finasteride commonly associated with reversible sexual side effects and dutasteride used off-label with similar risks.

This study suggests that 5α-reductase inhibitors do not significantly affect male reproductive function but may require caution in men with oligospermia or ejaculatory issues.

This review discusses the characteristics and diagnostic methods of androgenetic alopecia and reports no new clinical results; it highlights trichoscopy as a key tool, replacing scalp biopsies.

This review presents studies on plants used in Mexico to treat alopecia and reports no new clinical results.

Finasteride reduces the need for prostate surgery but may increase the risk of depression and persistent sexual side effects.

This study observed that long-term treatment with 5ARIs in men with LUTS/BPH was linked to worsening sexual function, whereas doxazosin alone had minimal negative impact.

Using hair loss drugs finasteride and dutasteride may cause sexual side effects.

This article provides background information on hereditary hair loss and indicates it can begin in women as early as age 30, but presents no new results.

In this study, patients who were informed about finasteride's sexual side effects reported them significantly more often than those who were not, highlighting a potential nocebo effect.

Finasteride can cause sexual side effects like decreased libido and erectile dysfunction.

This study concluded that dutasteride 0.5 mg/day improved hair growth in patients with androgenetic alopecia over six months but was associated with a higher prevalence of sexual dysfunction.

This meta-analysis reported that dutasteride was more effective than finasteride in increasing hair count and improving visual hair appearance in men with androgenetic alopecia over a 24-week period, while both drugs had similar rates of sexual dysfunction side effects.

This study found that patients using finasteride were up to twice as likely to experience sexual dysfunction, including ejaculation disorder, decreased libido, and impotence, compared to those not using the drug.

Finasteride and dutasteride, used for prostate issues and hair loss, can cause side effects like sexual dysfunction and mental issues, which may continue even after stopping the medication, a condition called post-finasteride syndrome, for which there's currently no cure.

Finasteride, a hair loss drug, can cause sexual side effects like erectile dysfunction in 2.1%-3.8% of users, but these usually go away with time or if the drug is stopped. Despite this, its impact on sexual function is minimal for most men.